Paratek Expands Management Team With Appointment of John P. Dunphy as CFO

Mar 03, 2005, 00:00 ET from Paratek Pharmaceuticals, Inc.

    BOSTON, March 3 /PRNewswire/ -- Paratek Pharmaceuticals, Inc. announced
 today the appointment of John P. Dunphy to the position of Vice President and
 Chief Financial Officer.  As CFO, Mr. Dunphy will have overall responsibility
 for the Company's finance, accounting and investor relations functions,
 building on more than 25 years of capital markets experience on Wall Street
 working with private and public companies. Executive management team member
 Beverly A. Armstrong will continue to direct internal operations as Vice
 President of Administration and has been appointed to the newly created
 positions of General Counsel and Chief Compliance Officer, where she will
 focus on governance, risk management and Sarbanes-Oxley compliance.
     Mr. Dunphy's expertise in equity and debt syndicate efforts includes a 13-
 year tenure as a Managing Director of SG Cowen's Equity Capital Markets Group
 (1989 to 2002).  At Cowen, Mr. Dunphy focused on structuring, marketing and
 syndicating the firm's healthcare transactions.  In 2002, he assumed the role
 of Chief Financial Officer at Idenix Pharmaceuticals, where, among other
 things, he provided financial leadership during the Idenix team's negotiation
 of a significant collaboration with Novartis.
     Prior to joining SG Cowen, Mr. Dunphy served as a Senior Vice President
 and Syndicate Manager at Butcher & Singer, where he was also a member of the
 company's Board of Directors.  Mr. Dunphy was also General Partner and Head of
 Syndicate at McDonald & Company Securities.  He is active in several
 securities industry professional associations and is a member of the Board of
 Governors of the Bond Club of New York and was a member of The Syndicate
 Committee of the Securities Industry Association.  Mr. Dunphy received his
 M.B.A. degree from Ohio State University and his B.A. degree in Economics from
 Boston College.
     "As Paratek prepares to enter the next stage of its life, Jack's depth of
 financial expertise and public markets experience, along with his track record
 with healthcare and biotech companies, will be invaluable to Paratek,"
 commented Paratek Pharmaceuticals' Chief Executive Officer, Thomas J. Bigger.
 "Jack has directly participated in many of the success stories in this
 industry, particularly in his role as a managing director at SG Cowen's Equity
 Capital Markets Group, and we believe his perspective will be crucial in
 Paratek's continued success as well."
     Beverly Armstrong commented, "Jack is a Wall Street veteran with unmatched
 capabilities and expertise. We are extremely pleased that the strength and
 depth of Paratek's scientific platforms and product pipeline have attracted
 him to our management team as we near an inflection point in Paratek's
     About Paratek Pharmaceuticals
     Paratek Pharmaceuticals, Inc. is engaged in the discovery and
 commercialization of new therapeutics that treat serious and life-threatening
 diseases, with a particular focus on the growing worldwide problem of
 antibiotic resistance.  Paratek's lead programs are advancing novel compounds
 that can circumvent or block bacterial resistance, as well as drugs that can
 prevent infection by interfering with Multiple Adaptational Response (MAR)
 mechanisms in bacteria.  Out of these efforts, Paratek has discovered a new
 class of antibiotics, the aminomethylcyclines that target the need for new and
 potent antibacterials to overcome the problem of rapidly growing bacterial
 resistance.  The Company's lead antibiotic clinical candidate, PTK 0796, the
 first product from this class, is being developed for the treatment of serious
     Outside the antibacterial therapeutic area, Paratek has also established
 an internal effort to exploit its novel families of compounds and their unique
 mechanism of action in selected anti-inflammatory and neurodegenerative
 conditions.  Paratek has an active chemical synthesis effort to produce novel
 and diverse small molecules, with the goal of developing non-antibacterial
 products with improved activity in serious diseases based upon a growing body
 of clinical and basic research supporting this approach.
     Paratek is privately held and headquartered in Boston, Massachusetts, USA.
 For more information, visit Paratek's website at

SOURCE Paratek Pharmaceuticals, Inc.